Cyclotek is currently engaged to manufacture PET tracers for clinical trials relating to:

  • Alzheimer’s
  • Parkinson Disease
  • Multiple Sclerosis
  • Prostate Cancer
  • Melanoma
  • Brain tumours, etc

Cyclotek has the capacity to manufacture PET radiopharmaceuticals for research and clinical trials under contract; in particular, radiopharmaceuticals for use in Phase II/III trials manufactured under GMP.

Cyclotek operates dedicated production and QC facilities for investigational products. The capacity exists to:

  • Implement client’s synthesis and radiolabelling protocols on existing synthesis modules at Cyclotek,
  • Accommodate client’s proprietary modules in dedicated hotcells for the duration of the trial,
  • Provide complete regulatory framework, including development of Standard Operating Procedures,
  • Validation and QC protocols specific to the product,
  • Manufacture and distribute the product throughout Australia and New Zealand.

On completion of trials, Cyclotek can offer contract or licensed manufacture of commercial product.